Genisphere Company Profile
Genisphere LLC is a nanotechnology company providing innovative tools for targeted drug delivery, clinical diagnostics and life science research based on the company’s 3DNA nanoparticle platform. Genisphere's unique, IP-protected, 3DNA® technology has broad applicability to improve the sensitivity in immunoassay and nucleic acid detection platforms, as well as to deliver therapeutics in a highly specific manner. Genisphere has successfully out-licensed several reagent kits to the research market, and provides customized products to improve the limit of detection of high-sensitivity lateral flow point-of-care tests, enabling their commercialization. Genisphere's diagnostic partners have a competitive advantage due to 3DNA’s ability to improve their test’s sensitivity, with minimal additional costs and no alterations to end-user protocols. For targeted therapeutics, Genisphere provides a fully customizable
all-DNA drug delivery platform. Genisphere's robust nanocarrier delivers small drug, RNAi and gene construct therapeutics with greatly improved efficacy and reduced toxicity. The company is continuing to seek partnerships with biotechnology and pharmaceutical companies that could benefit from Genisphere's platform technology
News from Genisphere:
Genisphere Signs Collaborative Research, Option to License Agreement with MedImmune
HATFIELD, Pa., June 2, 2016 /PRNewswire/ — Genisphere LLC, provider of the 3DNA® drug delivery platform, today announced it has executed a collaborative research and option to license agreement with MedImmune, the global biologics research and development arm of AstraZeneca. Under the agreement, MedImmune and Genisphere will develop novel nanoparticles utilizing its 3DNA dendrimer scaffold with […]
Genisphere Enters Collaborative Research Agreement with the University of Pennsylvania
HATFIELD, Pa., March 22, 2016 /PRNewswire/ — Genisphere LLC has signed a collaborative research agreement with the University of Pennsylvania to study targeted nanotherapeutics in cancer treatment. The collaboration between Genisphere LLC, provider of the 3DNA® drug delivery platform, and the University of Pennsylvania, through Dr. Theresa Busch, will utilize a breast cancer model to […]
Genisphere Awarded Patent for Cellular Delivery of siRNA and other Therapeutics using 3DNA® Nanocarrier
HATFIELD, Pa., Dec. 10, 2015 /PRNewswire/ — Genisphere LLC, provider of the 3DNA® nanotechnology platform, reported today it has been granted a patent titled "DNA dendrimers protected against nuclease degradation are useful as vectors for the delivery of siRNA" from the European Patent Office. The patent includes claims for keeping the company's DNA-based therapeutic nanocarrier (trademarked […]
Genisphere Closes $4 Million for Expansion of 3DNA® Targeted Drug Delivery Platform
HATFIELD, Penn., Oct. 1, 2015 /PRNewswire/ — Genisphere LLC, provider of the 3DNA® nanotechnology platform, announced it has closed a $4mm equity round. This round of fundraising will extend and expand development of Genisphere's targeted drug delivery platform, with the goal to license the 3DNA® platform to pharmaceutical partners and complete the pre-clinical work necessary to […]
Genisphere Appoints New CEO, Thomas Bliss
Biotechnology Company Strengthens Operating Team HATFIELD, Pa., June 30, 2015 /PRNewswire/ — Genisphere announced Tom Bliss has joined the company as CEO to help further develop Genisphere's therapeutics capabilities and portfolio. Mr. Bliss comes with a wealth of partnering experience, having spent much of the last 25 years in leadership positions at biopharmaceutical companies including […]
Genisphere's 3DNA® Drug Delivery Platform Achieves Success in Preclinical Treatment of Posterior Capsular Opacification (PCO)
HATFIELD, Pa., March 26, 2015 /PRNewswire/ — Genisphere LLC, provider of the 3DNA® nanotechnology platform, reported today it has achieved specific immunodepletion of problematic Myo/Nog cells implicated in posterior capsular opacification (PCO), a clouding of the eye lens which can be a complication of cataract surgery. The company envisions a wide application of this immunodepletion strategy […]
Genisphere Awarded Patent for Whole Transcriptome Next Generation Sequencing
HATFIELD, Pa., Feb. 10, 2014 /PRNewswire/ — Genisphere LLC reported today it has been granted a US patent for a novel strand-specific library preparation method for next generation sequencing based on its proven RNA amplification technology. The new patented process enables amplification and library preparation from clinically relevant RNA samples, adapts easily to a variety of […]
Genisphere Develops a Universal Signal Amplification Process for Lateral Flow Rapid Test Applications
HATFIELD, Pa., Oct. 7, 2013 /PRNewswire/ — Genisphere LLC reported today it has adapted its 3DNA® Nanotechnology for use as a universal signal amplification system for improving the sensitivity and overall performance of rapid diagnostic tests and applications. Detailed in a patent application submitted on August 16th, the new process is a further enhancement of the 3DNA® Signal Amplification technology, […]
